Q32 Bio Inc.
QTTB
$1.63
-$0.055-3.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -487.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -487.88% |
| Cost of Revenue | 26.45% | 92.23% | 67.28% | 24.41% | -9.26% |
| Gross Profit | 54.15% | -156.00% | -178.70% | -98.29% | -325.16% |
| SG&A Expenses | 41.77% | 103.65% | 83.03% | 107.55% | 12.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.31% | 94.82% | 70.98% | 43.83% | -4.65% |
| Operating Income | 43.72% | -141.27% | -146.31% | -101.32% | -226.24% |
| Income Before Tax | 41.10% | -25.98% | -167.42% | 117.62% | -177.26% |
| Income Tax Expenses | -733.99% | -- | -- | -- | 1,388.24% |
| Earnings from Continuing Operations | 47.58% | -25.40% | -192.37% | 115.05% | -179.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.58% | -25.40% | -192.37% | 115.05% | -179.39% |
| EBIT | 43.72% | -141.27% | -146.31% | -101.32% | -226.24% |
| EBITDA | 43.91% | -143.56% | -148.89% | -103.15% | -230.01% |
| EPS Basic | 98.47% | 96.40% | 91.50% | 105.21% | -5,529.56% |
| Normalized Basic EPS | 95.53% | 96.53% | 92.22% | 106.10% | -4,196.48% |
| EPS Diluted | 98.47% | 96.40% | 91.49% | 68.11% | -5,529.56% |
| Normalized Diluted EPS | 95.53% | 96.53% | 92.22% | 102.60% | -4,196.48% |
| Average Basic Shares Outstanding | 3,336.99% | 3,387.27% | 3,338.98% | 188.83% | -95.04% |
| Average Diluted Shares Outstanding | 3,336.99% | 3,387.27% | 3,338.98% | 577.37% | -95.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |